| Interventions |
Group 1: IBD-patients (age at enrollment 18-80 years) receiving a new treatment with vedolizumab. A former treatment with biologics will be allowed. More than 30% of patients with Vedolizumab therapy will be biologics-naiv. Group 2: IBD-patients (age at enrollment: 18-80 years) receiving a newly introduced anti TNF-alpha therapy other than Vedolizumab in biologics-naiv patients. Group 3: IBD-patients (age at enrollment: 18-80 years) with an early disease, who were first diagnosed <2 yaers befor the start of documentation in the investigator initiated non-interventional study (NIS) but have not yet received and are not planned to receive biologics in the near future. |